{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01129739",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CZheng"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "No. 30670903",
            "SecondaryIdType": "Other Identifier",
            "SecondaryIdDomain": "National Natural Science Foundation of China"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Shandong University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Myelodysplastic Syndromes",
      "OfficialTitle": "Phase II Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat RA and RARS of MDS"
    },
    "StatusModule": {
      "StatusVerifiedDate": "May 2010",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "May 2010"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "May 2013",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "May 2013",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "May 17, 2010",
      "StudyFirstSubmitQCDate": "May 24, 2010",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "May 25, 2010",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "May 24, 2010",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "May 25, 2010",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyOldNameTitle": "Chengyun Zheng",
        "ResponsiblePartyOldOrganization": "Department of Hematology of the 2nd Hospital of Shandong University"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Shandong University",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "National Natural Science Foundation of China",
            "CollaboratorClass": "OTHER_GOV"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) derived from human umbilical cord/placenta at a dose of 1.0E+6 MSC/kg on the subjects for refractory anemia (RA) and refractory anemia with ring sideroblast (RARS) of myelodysplastic syndromes (MDS).",
      "DetailedDescription": "Myelodysplastic syndromes are bone marrow stem cell disorders resulting in disorderly and ineffective hematopoiesis. MDS is characterized by variable degrees of cytopenias (anemia, neutropenia, and thrombocytopenia ) and risk of transformation to leukemia.\n\nTo date treatment of MDS is unsatisfactory: chemotherapy has a limited role in the management of leukemic progression; autologous stem cell transplantation does not prolong relapse-free survival and stem cell transplantation is poorly tolerated in older individuals. Some MDS patients have been shown to respond to a wide variety of immunosuppressive agents ranging from corticosteroids to CsA and antithymocyte globulin (ATG). However, the overall response rate is less than 30%. In fact, few treatments appear to change the natural history of MDS.\n\nThe management of MDS patients therefore remains to be improved. Human MSCs isolated from Wharton's jelly of the umbilical cord/placenta have been shown to have immunosuppressive, stimulating hematopoiesis and tissue repairing properties. This study will evaluate the safety and effectiveness of MSC transplant in the MDS patients.\n\nThis study will last about 3 years. Participants will be randomly assigned to receive either MSC transplant (Group 1) or CsA therapy alone (Group 2). Patients will undergo MSC transplant at the start of the study (defined as Day 0). After 3 months, patients will receive the second MSC transplantation when one responds well to the treatment. After 3, 6 and 12 months from the first transplantation, patients will be evaluated."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Myelodysplastic Syndromes"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Bone Marrow Disease",
          "MDS-RA",
          "MDS-RARS",
          "Umbilical Cord/placenta-Derived MSC",
          "Transplant"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Single",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "30",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Human umbilical cord-derived MSCs",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated to apply in trimonthly for 2 cycle",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Human umbilical cord-derived MSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "cyclosporine A (CsA)",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "CsA at a dose of 5 mg CsA/kg",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: cyclosporine A (CsA)"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Other",
            "InterventionName": "Human umbilical cord-derived MSCs",
            "InterventionDescription": "1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Human umbilical cord-derived MSCs"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "cyclosporine A (CsA)",
            "InterventionDescription": "CsA 5mg/kg po for 6 months",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "cyclosporine A (CsA)"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "MDS clinical symptoms (mainly anemia symptoms)",
            "PrimaryOutcomeDescription": "Anemia symptoms will be mainly observed in every week after transplanting MSCs for one year.",
            "PrimaryOutcomeTimeFrame": "1 year"
          },
          {
            "PrimaryOutcomeMeasure": "A routine blood test",
            "PrimaryOutcomeDescription": "A routine blood test, which contains WBC, Neu, RBC, Hb and PLT, will be mainly tested in every month after transplanting MSCs for one year.",
            "PrimaryOutcomeTimeFrame": "1 year"
          },
          {
            "PrimaryOutcomeMeasure": "Bone borrow cytomorphologic examination",
            "PrimaryOutcomeDescription": "Bone borrow cytomorphologic examination will be tested in every 3 months after transplanting MSCs for one year.",
            "PrimaryOutcomeTimeFrame": "1 year"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Percentage of T regulatory cell population in peripheral blood",
            "SecondaryOutcomeDescription": "Percentage of T regulatory cell population in peripheral blood will be tested in every 3 months after transplanting MSCs for one year.",
            "SecondaryOutcomeTimeFrame": "1 year"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPatient age 18~80 years old with plan to infuse MSCs.\nHistologically documented or cytologically confirmed diagnosis of MDS with WHO classification of MDS-RA and MDS-RARS.\nPatients must have an ECOG 0~2.\nNo moderate or sever organ dysfunction: Ejection fraction>45%; Creatinine <176 mmol/L.\nNo active severe viral or fungus infection.\nEach patient must sign written informed consent.\n\nExclusion Criteria:\n\nPsychiatric condition that would limit informed consent.\nHIV positive\nPositive Pregnancy Test\nPatient has enrolled another clinical trial study within last 4 weeks.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "80 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "chengyun zheng, PhD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+86-531-85875635",
            "CentralContactEMail": "chengyun.zheng@ki.se"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "cheng yun zheng, PhD",
            "OverallOfficialAffiliation": "Department of Hematology of The 2nd Hospital of Shandong University",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Department of Hematology of the 2nd Hospital of Shandong University",
            "LocationStatus": "Recruiting",
            "LocationCity": "Jinan",
            "LocationState": "Shandong",
            "LocationZip": "250033",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Chengyun Zheng, PhD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+86-531-85875635",
                  "LocationContactEMail": "chengyun.zheng@ki.se"
                },
                {
                  "LocationContactName": "chengyun zheng, PhD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000011289",
            "ConditionMeshTerm": "Preleukemia"
          },
          {
            "ConditionMeshId": "D000009190",
            "ConditionMeshTerm": "Myelodysplastic Syndromes"
          },
          {
            "ConditionMeshId": "D000013577",
            "ConditionMeshTerm": "Syndrome"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000004194",
            "ConditionAncestorTerm": "Disease"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000001855",
            "ConditionAncestorTerm": "Bone Marrow Diseases"
          },
          {
            "ConditionAncestorId": "D000006402",
            "ConditionAncestorTerm": "Hematologic Diseases"
          },
          {
            "ConditionAncestorId": "D000011230",
            "ConditionAncestorTerm": "Precancerous Conditions"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M15507",
            "ConditionBrowseLeafName": "Syndrome",
            "ConditionBrowseLeafAsFound": "Syndrome",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M4286",
            "ConditionBrowseLeafName": "Bone Marrow Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11297",
            "ConditionBrowseLeafName": "Myelodysplastic Syndromes",
            "ConditionBrowseLeafAsFound": "Myelodysplastic Syndrome",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M13316",
            "ConditionBrowseLeafName": "Preleukemia",
            "ConditionBrowseLeafAsFound": "Myelodysplastic Syndrome",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M8642",
            "ConditionBrowseLeafName": "Hematologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13263",
            "ConditionBrowseLeafName": "Precancerous Conditions",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3993",
            "ConditionBrowseLeafName": "Myelodysplastic Syndromes",
            "ConditionBrowseLeafAsFound": "Myelodysplastic Syndrome",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC15",
            "ConditionBrowseBranchName": "Blood and Lymph Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000016572",
            "InterventionMeshTerm": "Cyclosporine"
          },
          {
            "InterventionMeshId": "D000003524",
            "InterventionMeshTerm": "Cyclosporins"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000004791",
            "InterventionAncestorTerm": "Enzyme Inhibitors"
          },
          {
            "InterventionAncestorId": "D000045504",
            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
          },
          {
            "InterventionAncestorId": "D000007166",
            "InterventionAncestorTerm": "Immunosuppressive Agents"
          },
          {
            "InterventionAncestorId": "D000007155",
            "InterventionAncestorTerm": "Immunologic Factors"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          },
          {
            "InterventionAncestorId": "D000000935",
            "InterventionAncestorTerm": "Antifungal Agents"
          },
          {
            "InterventionAncestorId": "D000000890",
            "InterventionAncestorTerm": "Anti-Infective Agents"
          },
          {
            "InterventionAncestorId": "D000003879",
            "InterventionAncestorTerm": "Dermatologic Agents"
          },
          {
            "InterventionAncestorId": "D000018501",
            "InterventionAncestorTerm": "Antirheumatic Agents"
          },
          {
            "InterventionAncestorId": "D000065095",
            "InterventionAncestorTerm": "Calcineurin Inhibitors"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M18113",
            "InterventionBrowseLeafName": "Cyclosporine",
            "InterventionBrowseLeafAsFound": "2 weeks",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M5882",
            "InterventionBrowseLeafName": "Cyclosporins",
            "InterventionBrowseLeafAsFound": "2 weeks",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M9364",
            "InterventionBrowseLeafName": "Immunosuppressive Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9353",
            "InterventionBrowseLeafName": "Immunologic Factors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M5404",
            "InterventionBrowseLeafName": "Clotrimazole",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M10948",
            "InterventionBrowseLeafName": "Miconazole",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3406",
            "InterventionBrowseLeafName": "Antifungal Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3366",
            "InterventionBrowseLeafName": "Anti-Infective Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M6226",
            "InterventionBrowseLeafName": "Dermatologic Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M19757",
            "InterventionBrowseLeafName": "Antirheumatic Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M29605",
            "InterventionBrowseLeafName": "Calcineurin Inhibitors",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ARhu",
            "InterventionBrowseBranchName": "Antirheumatic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "Derm",
            "InterventionBrowseBranchName": "Dermatologic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}